Date: 2026-04-11 | Holdings: 4 | Top-3: 75.0% | HHI: 0.25 (~4.0 names)
Japan equities face a mixed backdrop in April 2026: the BOJ continues rate normalization (short-term prime rate at 2.125%, highest in ~30 years), boosting bank earnings but tightening conditions for leveraged sectors. U.S. tariff escalation is a major headwind for exporters—Toyota estimates a ¥1.45T impact and Sony flags ~¥100B. The yen remains volatile around 150/USD, and domestic consumption is recovering unevenly amid persistent cost-push inflation.
Verified against StockAnalysis.com. Forward PE cross-checked.
| Stock | Ticker | Wt | Conv | PE | Fwd PE | P/B | ROE | OpM | D/E | DY | FCF |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sony Group | 6758.T | 25% | MED | 15.93 | 18.38 | 2.82 | 14.92% | 12.48% | 19% | 0.76% | +¥1,620B |
| Toyota Motor | 7203.T | 25% | HIGH | 9.97 | 13.95 | 1.0 | 12.94% | 8.76% | 104% | 2.71% | +¥350B |
| Mitsubishi UFJ Financial Group | 8306.T | 25% | HIGH | 15.59 | 13.37 | 1.28 | 9.08% | 42.6% | 389% | 2.60% | +¥930B |
| Daiichi Sankyo | 4568.T | 25% | MED | 18.5 | 33.0 | 3.4 | 15.59% | 17.25% | 6% | 1.39% | +¥200B (est) |
WHY this stock: Diversified entertainment-tech conglomerate with dominant ~56% global CMOS image sensor share, record 132M monthly active PlayStation users, and growing music/anime IP portfolio (Crunchyroll 17M+ subs, KADOKAWA 10% stake). Post-spinoff of financial services (Oct 2025) the corporate structure is cleaner. Trailing PE of 15.9x with 14.9% ROE and very low leverage (D/E 0.19) on ¥1.62T FCF.
What could go wrong: Forward PE of 18.4x implies earnings deceleration. Apple reportedly diversifying CMOS sensor supply to Samsung (~2027), threatening Sony's sensor exclusivity. PS5 is late-cycle with PS6 delayed to 2028-2029. ~¥100B tariff headwind on hardware segments. S&P Global forecasts 7.4% revenue decline in FY2026.
Monitoring trigger: If Samsung confirmed as Apple sensor supplier for iPhone 18, reassess I&SS segment. If PS6 timeline slips past 2029 or FCF drops below ¥1T, reduce conviction.
Key customers: [CONFIRMED] Apple (CMOS image sensors (IMX803 for iPhone)); [CONFIRMED] Samsung/Xiaomi (CMOS image sensors for smartphones); [CONFIRMED] KADOKAWA (Anime/game IP licensing); [CONFIRMED] TCL (TV/home audio JV (51% TCL, 49% Sony));
WHY this stock: World's largest automaker for 6th consecutive year (11.3M vehicles in 2025) trading at just 10.0x trailing PE and P/B near 1.0x—well below auto industry average of 18.0x. Record revenue of ¥49.4T with 2.71% dividend yield. Dominant hybrid franchise (planning 6.7M units/year by 2028) is proving prescient as global BEV adoption slows. $10B committed to U.S. manufacturing. Unanimous analyst buy consensus with ¥4,022 target (~23% upside).
What could go wrong: U.S. tariffs are a ¥1.45T headwind—operating income forecast cut by ¥600B to ¥3.2T. BEV production target scaled back to 800K (from 1.5M), risking strategic lag if EV tipping point accelerates. FCF declined 67% YoY to ~¥350B in FY2025. BYD aggressively expanding in Toyota's key SE Asian markets.
Monitoring trigger: If tariff impact exceeds ¥1.5T or BYD enters SE Asia at scale, reassess. Cut if FCF stays below ¥400B for 2+ quarters or D/E exceeds 1.5x.
Key customers: [CONFIRMED] US consumers/fleets (Vehicles (2.93M units sold in US, +7.3%)); [CONFIRMED] Denso Corporation (Electronic/fuel components (upstream)); [CONFIRMED] Aisin Corporation (Transmissions/chassis systems (upstream)); [CONFIRMED] Waymo (Autonomous driving technology partnershi);
WHY this stock: Japan's largest megabank (~¥2.7T total assets, 8.4% domestic loan share) is the prime beneficiary of BOJ rate normalization—prime rate at 2.125% (30-year high) is directly boosting net interest income. Record H1 FY2025 profits of ¥1.29T; Q3 net income up 6% YoY. Forward PE of 13.4x with 2.6% dividend yield and 42.6% operating margin. The 22% Morgan Stanley stake adds global IB/AM diversification. Stock up +38% over 52 weeks with analyst consensus buy.
What could go wrong: D/E of 389% is structurally high (normal for megabanks) but amplifies credit risk. If BOJ overshoots on tightening and triggers recession, loan demand drops and NPLs rise. Large M&A pipeline (Shriram Finance ~¥500B, GCash $393M, EU Universal Bank) carries integration risk. ROE of 9.1% still below 12% management target.
Monitoring trigger: If BOJ signals rate pause or reversal, reassess rate tailwind thesis. If NPL ratio rises above 1.5% or ROE fails to reach 12% by FY2027, reduce conviction.
Key customers: [CONFIRMED] Morgan Stanley (22% equity stake + JV securities); [CONFIRMED] 400K+ corporate clients (Commercial banking/lending (¥131.9T loan); [PROBABLE] Shriram Finance (India) (~20% stake acquisition (~¥500B)); [CONFIRMED] GCash (Philippines) ($393M digital payments investment);
WHY this stock: Global leader in antibody-drug conjugates (ADCs) with proprietary DXd platform. Flagship Enhertu achieved ~¥553B in 9-month FY2025 sales (AZ combined $3.75B in CY2024). AstraZeneca co-commercialization plus $22B-potential Merck deal for 3 ADCs validates the platform. Five ADC launches planned for 2026 including Enhertu 1st-line breast cancer (FDA approved Jan 2026). Won patent battle vs Seagen/Pfizer. Revenue growing +14% YoY to ¥2.05T with 15.6% ROE and near-zero leverage (D/E 6%).
What could go wrong: Stock down -20% over 52 weeks reflecting pipeline repricing after patritumab deruxtecan FDA failure (1 of 3 Merck ADCs). Forward PE of ~33x is elevated vs. pharma peers. R&D spend of ¥455B is aggressive; FCF unconfirmed and flagged as dividend-coverage concern. Heavy Enhertu concentration risk with patent cliff ~2033. ADC space rapidly crowding with 100+ candidates in clinical development globally.
Monitoring trigger: If I-DXd or R-DXd Phase III data disappoints at ASCO 2026, cut position. If FCF turns negative for 2 consecutive quarters, reduce to LOW. Watch Enhertu quarterly sales for deceleration signs.
Key customers: [CONFIRMED] AstraZeneca (Enhertu co-development/co-commercializat); [CONFIRMED] Merck (3 DXd ADCs ($22B total-potential deal)); [CONFIRMED] Imagene AI (Oncology biomarker discovery); [CONFIRMED] Tempus AI (AI-driven clinical development);
| Layer | Weight | Stocks |
|---|---|---|
| Technology/Entertainment | 25% | 6758.T |
| Automotive/Manufacturing | 25% | 7203.T |
| Financials/Banking | 25% | 8306.T |
| Healthcare/Pharma | 25% | 4568.T |
| StockAnalysis.com — TYO:6758, TYO:7203, TYO:8306, TYO:4568 (Apr 2026) | ||
| Yahoo Finance — 6758.T, 7203.T, 8306.T, 4568.T key statistics (Apr 2026) | ||
| Investing.com — financial ratios and real-time quotes (Apr 2026) | ||
| GuruFocus — P/B ratios, ROE, valuation metrics | ||
| MacroTrends — historical free cash flow data | ||
| AstraZeneca press releases — Enhertu regulatory milestones (Jan-Apr 2026) | ||
| Merck press releases — DXd ADC collaboration details (Oct 2023) | ||
| Japan Times / Nikkei — BOJ rate decisions, MUFG earnings, Toyota sales records | ||
| Company IR pages — Sony, Toyota, MUFG, Daiichi Sankyo (FY2025 guidance) |
Generated by JPstock-agent (remote trigger) | 2026-04-11 | AI-assisted research, not investment advice